Phase III Trial of Pazopanib in Metastatic Kidney Cancer Post-Surgery
A phase III trial is evaluating the efficacy of pazopanib hydrochloride versus placebo in patients with metastatic kidney cancer post-surgery.
Therapeutic Area
Therapeutic area intelligence for Kidney Cancer with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.